Chao Qiang Jiang 1 , Lin Xu 2,3 , Tai Hing Lam 1,3 , Ya Li Jin 1 , Wei Sen Zhang 1 , Feng Zhu 1 , G Neil Thomas 4 , Kar Keung Cheng 4 Show Affiliations »
Abstract
CONTEXT: China has the largest number of people with type 2 diabetes mellitus (T2DM) in the world. Data from previous studies have suggested that up to one-fifth of individuals with diabetes would be missed without an oral glucose tolerance test (OGTT). To date, there is little information on the mortality risk of these individuals. OBJECTIVE: We estimated the association of different indicators of hyperglycemia with mortality in the general Chinese population. DESIGN: Prospective cohort study. SETTING: China. PARTICIPANTS: A total of 17 939 participants aged 50+ years. EXPOSURES: Previously diagnosed diabetes and newly detected diabetes defined by fasting glucose (≥7.0 mmol/L), 2-hour postload glucose (≥11.1 mmol/L), or hemoglobin A1c (HbA1c, ≥6.5%). MAIN OUTCOMES MEASURES: Deaths from all-cause, cardiovascular disease, and cancer were identified by record linkage with death registration. RESULTS: During 7.8 (SD, 1.5) years' follow-up, 1439 deaths were recorded. Of 3706 participants with T2DM, 2126 (57%) had known T2DM, 118 (3%) were identified by isolated elevated fasting glucose, 1022 (28%) had isolated elevated postload glucose, and 440 (12%) had both elevated fasting and postload glucose. Compared with normoglycemia, the hazard ratio (95% confidence interval) of all-cause mortality was 1.71 (1.46-2.00), 0.96 (0.47-1.93), 1.43 (1.15-1.78), and 1.82 (1.35-2.45) for the 4 groups, respectively. T2DM defined by elevated HbA1c was not significantly associated with all-cause mortality (hazard ratio, 1.17; 95% confidence interval, 0.81-1.69). CONCLUSION: Individuals with isolated higher 2-h postload glucose had a higher risk of mortality by 43% than those with normoglycemia. Underuse of OGTT leads to substantial underdetection of individuals with a higher mortality risk and lost opportunities for early intervention. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CONTEXT: China has the largest number of people with type 2 diabetes mellitus (T2DM ) in the world. Data from previous studies have suggested that up to one-fifth of individuals with diabetes would be missed without an oral glucose tolerance test (OGTT). To date, there is little information on the mortality risk of these individuals. OBJECTIVE: We estimated the association of different indicators of hyperglycemia with mortality in the general Chinese population. DESIGN: Prospective cohort study. SETTING: China. PARTICIPANTS : A total of 17 939 participants aged 50+ years. EXPOSURES: Previously diagnosed diabetes and newly detected diabetes defined by fasting glucose (≥7.0 mmol/L), 2-hour postload glucose (≥11.1 mmol/L), or hemoglobin A1c (HbA1c, ≥6.5%). MAIN OUTCOMES MEASURES: Deaths from all-cause, cardiovascular disease , and cancer were identified by record linkage with death registration. RESULTS: During 7.8 (SD, 1.5) years' follow-up, 1439 deaths were recorded. Of 3706 participants with T2DM , 2126 (57%) had known T2DM , 118 (3%) were identified by isolated elevated fasting glucose , 1022 (28%) had isolated elevated postload glucose , and 440 (12%) had both elevated fasting and postload glucose . Compared with normoglycemia, the hazard ratio (95% confidence interval) of all-cause mortality was 1.71 (1.46-2.00), 0.96 (0.47-1.93), 1.43 (1.15-1.78), and 1.82 (1.35-2.45) for the 4 groups, respectively. T2DM defined by elevated HbA1c was not significantly associated with all-cause mortality (hazard ratio, 1.17; 95% confidence interval, 0.81-1.69). CONCLUSION: Individuals with isolated higher 2-h postload glucose had a higher risk of mortality by 43% than those with normoglycemia. Underuse of OGTT leads to substantial underdetection of individuals with a higher mortality risk and lost opportunities for early intervention. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Chemical
Disease
Species
Mesh： See more »
Substances： See more »
Year: 2020
PMID： 31679008 DOI： 10.1210/clinem/dgz173
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN： 0021-972X Impact factor: 5.958